Sargassum Alginate
Component A — Matrix formation
Haemostasis via calcium ion exchange. Activates the coagulation cascade on contact. Manages wound moisture during the evacuation window. Forms the structural matrix of every RAPIDHealth scaffold.
RAPIDHealth Platform — Biological Regeneration
RAPID
HEALTH
From a zero-cost ocean feedstock, using a proprietary non-thermal processing protocol that no prior art has described, RAPIDHealth can produce a family of biological scaffolds capable of regenerating every tissue the human body contains — starting with the soldier on the battlefield and ending with the Alzheimer's patient in the clinic.
Bio-Farm Supply Chain
The same pelagic sargassum harvest that produces marine biofuel, pharmaceutical bioactives and carbon credits for the Caribbean also provides the feedstock for every RAPIDHealth product. One supply chain. Zero cultivation cost. Climate change increases yield, not expense. No other pharmaceutical company has this.
THE SPINE OF EVERYTHING
Every prior art scaffold protocol uses thermal extraction. That single process decision makes every existing scaffold product inferior — and makes them all unachievable competitors to RAPIDHealth.
The critical distinction
Non-thermal processing is not an incremental improvement. It is the only processing route that preserves the two biological properties that make the entire RAPIDHealth platform possible. Without it, none of these products exist. With it, no competitor can replicate them.
What thermal processing destroys
Native fucoidan sulphation pattern — critical for NGF binding, osteoinduction, and neuroactive function. Destroyed at standard extraction temperatures. Cannot be restored or synthesised.
Living holobiont compound profile — the MRSA-active antimicrobials from the sargassum-associated microbial community. No synthetic process can replicate them. No commercially extracted fucoidan contains them.
What non-thermal processing preserves
Native fucoidan sulphation — drives MSC differentiation toward osteogenic lineage (RAPIDBone), promotes NGF binding for nerve repair (RAPIDNeural), enables active remyelination via PI3K/AKT/mTOR pathway
Living holobiont antimicrobials — documented MIC activity against MRSA and drug-resistant E. coli. Non-antibiotic mechanism. No cross-resistance to any existing antibiotic class.
Consistent compound profile — Bio-Farm controlled grow-out produces stable, reproducible holobiont. Same batch chemistry. Same clinical performance. Every time.
The non-thermal processing protocol is the subject of a UK patent application. No prior art describes this protocol in the sargassum context. The inventive step is confirmed across all five RAPIDHealth products.
FOUR COMPONENTS. ONE SOURCE.
Every RAPIDHealth product shares the same four-component chemistry — all extracted from the same arsenic-remediated pelagic sargassum harvest batch. The combination is novel. No prior art describes it.
Sargassum Fucoidan
Component B — The active driver
Procoagulant activity. 13-second wound seal gelation. Angiogenesis via Akt/Nrf2/HIF-1α pathway. Osteoinduction without exogenous growth factors. NGF binding for nerve repair. Active remyelination via PI3K/AKT/mTOR. Only native sulphation delivers this — only non-thermal processing preserves it.
Sargassum Phlorotannins
Component C — Antimicrobial layer
Anti-biofilm activity — prevents initial bacterial adhesion at the optimal intervention point. Non-antibiotic antimicrobial via membrane disruption. NF-κB/MAPK/COX-2/Nrf2 modulation. No cross-resistance to any existing antibiotic class identified.
Holobiont Antimicrobials
Component D — The irreplicable layer
Secondary metabolites from sargassum-associated microbial community. Documented MIC activity against MRSA and drug-resistant E. coli. Cannot be synthesised. Cannot be replicated from commercially extracted fucoidan. Unique to non-thermally-processed Bio-Farm harvest.
THE PLATFORM
Five clinical products. Same feedstock. Same chemistry. Same processing standard. Compatible degradation rates. No immunogenic mismatch. One company.
Related — GB2606416.2
Patent FiledRAPIDGel
Haemostatic Wound Management
The entry point. Stops bleeding. Seals the wound in 13 seconds. Delivers non-antibiotic MRSA-active antimicrobial protection from point of application. Closes the gap that every existing haemostatic dressing leaves open — none have intrinsic antimicrobial activity.
13-sec gelation
MRSA active
No cold chain
Self-aid application
View RAPIDGel
GB2607398.1
Patent FiledRAPIDSkin
Dermal Regeneration Scaffold
Lyophilised 3D porous scaffold. Rehydrates and conforms to wound geometry. Intrinsic antimicrobial, anti-inflammatory, and pro-angiogenic activity. No exogenous growth factors. No cold chain. Works where conventional dressings fail — burns, blast avulsion, chronic non-healing wounds.
Lyophilised
Self-conforming
No growth factors
Pro-angiogenic
View RAPIDSkin
GB2607402.1
Patent FiledRAPIDBone
Osseous Regeneration Scaffold
Sargassum matrix plus nano-hydroxyapatite. Retained fucoidan drives MSC differentiation toward osteogenic lineage — intrinsic osteoinduction without rhBMP. Eliminates oncogenic risk. Patient-specific geometry from CT imaging. No donor site. No growth factor injections.
Osteoinductive
No rhBMP
No donor site
CT geometry
View RAPIDBone
To file
Filing PendingRAPIDNeural
Peripheral Nerve Repair + Remyelination
Fucoidan-functionalised scaffold presenting NGF on surface — neurite outgrowth without exogenous NGF in solution. Exceeds the 25–30mm gap limitation of all current conduits. Promotes OPC differentiation into oligodendrocytes via PI3K/AKT/mTOR — active remyelination. The same mechanism implicated in MS, Parkinson's, and Alzheimer's neurodegeneration.
30mm+ gaps
Active remyelination
NGF surface binding
OPC differentiation
View RAPIDNeural
To file
Filing PendingRAPIDSystem
Integrated Multi-Tissue Reconstruction
Skin, bone, and nerve — simultaneously. One wound. One operation. One material. Shared origin means material compatibility, matched degradation rates, consistent antimicrobial profile, and zero immunogenic mismatch. Not achievable with any existing scaffold combination.
Single intervention
All three tissues
Compatible degradation
No mismatch
View RAPIDSystem
Platform Architecture
FROM BATTLEFIELD TO CLINIC
One supply chain. Every tissue. Two markets.
Combat is the entry point. The clinical validation, IP protection, and procurement relationships built through battlefield medicine create the foundation. Neurodegeneration is the global commercial scale. The same PI3K/AKT/mTOR remyelination mechanism that repairs blast-damaged peripheral nerves is the mechanism implicated in MS, Parkinson's, and Alzheimer's. Three diseases. Two hundred million patients. One platform.
Platform structure
RAPIDHealth Platform │ ├── Combat entry point │ ├── RAPIDGel — wound + antimicrobial │ ├── RAPIDSkin — dermal regeneration │ ├── RAPIDBone — osseous reconstruction │ ├── RAPIDNeural — peripheral nerve │ └── RAPIDSystem — all tissues, one op │ └── Neurological extension ├── MS — remyelination ├── Parkinson's — PI3K/AKT/mTOR └── Alzheimer's — neurodegeneration
POINT OF WOUNDING TO FUNCTIONAL RECOVERY
One platform. One supply chain. The complete clinical pathway — from the moment a soldier is hit to the moment they are functionally recovered.
T+0 — Point of wounding
RAPID Family
RAPIDPen arrests haemorrhagic shock. RAPIDPlasma resuscitates. RAPIDGel closes the wound — haemostasis in 13 seconds, MRSA-active antimicrobial protection active from application. Evacuation window extended from 36 to 68+ minutes.
T+5 to T+60 — Evacuation
SENTINEL + SDICS
SENTINEL detects the casualty autonomously. SDICS activates the donor coordination network. Compatible pre-screened donors move. Role 2 receives the full medical record before the casualty leaves the field. The trauma team is ready.
Role 2 / Role 3 — Surgical
RAPIDSystem
RAPIDSkin, RAPIDBone, RAPIDNeural applied simultaneously. One material. One source. One surgical intervention. Shared chemistry means material compatibility, matched degradation rates, zero immunogenic mismatch.
Recovery
Functional Recovery
Scaffold degrades as the patient's own tissue grows. Skin. Bone. Nerve. Simultaneously. No staged surgeries. No donor site morbidity. No rejected graft. The scaffold does its work and disappears.
THE NEUROLOGICAL EXTENSION
RAPIDNeural is not a peripheral nerve repair device. It is a remyelination platform. The PI3K/AKT/mTOR pathway that drives OPC differentiation into oligodendrocytes in a battlefield nerve wound is the same pathway implicated in three of the most commercially significant disease areas in medicine.
Combat provides clinical validation, regulatory precedent, and IP protection. Neurodegeneration provides the global commercial scale. The same chemistry. Different delivery. Two hundred million patients.
The mechanism link
OPC differentiation into myelinating oligodendrocytes via PI3K/AKT/mTOR — active in RAPIDNeural's peripheral nerve repair context, and the same failure of this pathway that underlies the neurodegeneration in MS, Parkinson's, and Alzheimer's disease. No approved therapy promotes active remyelination in any of these conditions. RAPIDHealth does not treat the symptoms. It addresses the mechanism.
Multiple Sclerosis
Mechanism — OPC → oligodendrocyte failure via PI3K/AKT/mTOR disruption
MS is defined by progressive demyelination and failure of remyelination. RAPIDNeural's fucoidan scaffold promotes the OPC differentiation that MS prevents. Different delivery to combat application. Same biochemistry. No approved remyelination therapy exists.
Parkinson's Disease
Mechanism — PI3K/AKT/mTOR pathway dysregulation in dopaminergic neurons
Dopaminergic neuron degeneration proceeds through PI3K/AKT/mTOR pathway disruption — the same pathway RAPIDNeural targets in peripheral nerve remyelination. The neuroprotective and neuroregenerative properties of the fucoidan formulation are under investigation for this indication.
Alzheimer's Disease
Mechanism — Neurodegeneration, amyloid cascade, myelin loss
Alzheimer's involves progressive neurodegeneration with myelin loss and failure of repair mechanisms. Fucoidan has demonstrated neuroprotective activity and inhibition of beta-amyloid aggregation in research contexts. RAPIDHealth's non-thermally-processed formulation preserves the native sulphation required for these mechanisms — absent in all commercially extracted fucoidan products.
Marine Division
Medical Division
WHERE THE OCEAN MEETS THE OPERATING TABLE
The Bio-Farm was designed as a sargassum interception and circular economy platform for the Caribbean. It produces marine biofuel, SAF, pharmaceutical bioactives, and carbon credits from a feedstock that costs nothing and doubles every 13 days.
RAPIDHealth is revenue stream 10 from that same harvest. The supply chain that solves a Caribbean coastal crisis also provides the feedstock for the most advanced biological scaffold platform in development. Climate change makes it more productive, not more expensive.
Explore the Bio-FarmOffshore interception
Bio-Farm net system captures pelagic sargassum before it beaches. Passive. Modular. Community-operated.
Input cost: £0
Controlled grow-out
Submerged cultivation with phosphate competitive inhibition to manage arsenic uptake. Biomass doubles every 13 days. Stable, reproducible holobiont compound profile.
Grows at: 2× per 13 days
Arsenic remediation
Three-stage management separates inorganic arsenic from organic arsenosugars. Pharmaceutical-grade inorganic arsenic limits achievable from every batch.
Regulatory: ICH Q3D compliant
Non-thermal extraction
Proprietary protocol preserves native fucoidan sulphation and living holobiont compound profile. Four-component chemistry separated. No prior art describes this protocol.
IP: UK patent application filed
Clinical product formulation
Same batch chemistry. Five products. Every tissue type. One pharmaceutical-grade supply chain.
Output: RAPIDGel, RAPIDSkin, RAPIDBone, RAPIDNeural, RAPIDSystem
IP POSITION
Six patent applications protect the RAPIDHealth platform. Each covers formulation, delivery formats, methods of use, and the pharmaceutical-grade supply chain protocol. Technical detail available under NDA.
GB2606416.2
Bio-Farm / RAPIDGel
Filed — March 2026
20 claims — formulation, delivery formats, supply chain protocol
GB2607398.1
RAPIDSkin
Filed — March 2026
Lyophilised dermal scaffold, non-thermal processing, holobiont retention
GB2607402.1
RAPIDBone
Filed — March 2026
Osseous regeneration scaffold, fucoidan osteoinduction, nano-HA composite
NTL-001 / 002 / 003
RAPID Family — Haemorrhagic Shock
Filed — March 2026
69 claims across three devices
NTL-004
SENTINEL / HEARTBEAT
Filed — March 2026
22 claims — dual-trigger biosensor architecture
RAPIDNeural / RAPIDSystem
Neural Repair + Integrated Scaffold
Filing in preparation
Peripheral nerve repair, remyelination, multi-tissue integration
Defence contractors · NHS · Research institutions · Investors
REQUEST A BRIEFING
Full technical documentation, patent applications, and clinical evidence base available under NDA to qualified research institutions, defence procurement, and investment partners. UKDI submission active. NATO Project DIANA pathway identified.